Attralus Presents New Preclinical Data on AT-04 and AT-07, Pan-Amyloid Removal Therapeutics Targeting Neurodegenerative Disorders, at AD/PD 2023
Retrieved on:
Monday, April 3, 2023
The data was presented in an oral presentation at the AD/PD™ 2023 International Conference on Alzheimer’s and Parkinson’s Diseases (March 28–April 1, 2023) in Gothenburg, Sweden.
Key Points:
- The data was presented in an oral presentation at the AD/PD™ 2023 International Conference on Alzheimer’s and Parkinson’s Diseases (March 28–April 1, 2023) in Gothenburg, Sweden.
- AT-04 alone demonstrated brain penetration similar to other monoclonal antibodies that have shown clinical efficacy in Alzheimer's Disease.
- AT-07, the conjugation of AT-04 to the Brain Shuttle, resulted in a 10-fold increase in mouse brain penetration versus AT-04.
- Abstract Title: Development of Brain Shuttle Enabled AT-04, a Novel Peptibody That Binds Neuropathologic Fibrillar Aggregates